ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Carotid intima-media thickness

Carotid intima-media thickness
Literature review current through: Aug 2023.
This topic last updated: Feb 28, 2022.

INTRODUCTION — Significant progress has been made to develop noninvasive atherosclerosis imaging techniques that can serve as validated biomarkers (surrogate end points) for cardiovascular health status, aid in the identification of disease risk factors, and identify and evaluate measures to prevent disease. One of the rationales for atherosclerosis imaging originates from autopsy studies in adolescents and young adults, which revealed that atherosclerosis is present early in life and precedes clinically manifested cardiovascular events. Therefore, non-invasive arterial imaging has the potential to provide information on arterial wall structure in persons of all age groups as a continuous variable to describe all stages of atherosclerosis progression and regression [1,2]. Consequently, using imaging to detect early atherosclerosis has the potential to identify the status and predict the risk of future cardiovascular events in populations, as well as evaluate existing and novel drug efficacy to guide cardiovascular therapies prior to the occurrence of atherosclerotic cardiovascular disease.

One of the most widely used and best validated atherosclerosis imaging techniques is the ultrasound carotid intima-media thickness (CIMT) measurement. The techniques for imaging and measuring CIMT along with the potential clinical applications of CIMT will be discussed here. Carotid artery imaging for the detection of significant obstruction carotid disease is discussed separately. (See "Evaluation of carotid artery stenosis".)

CIMT MEASUREMENT BY ULTRASOUND — CIMT can be measured using either high resolution ultrasound or magnetic resonance imaging (MRI). At present, carotid ultrasound has provided the majority of imaging data; however, with its increasing availability, MRI has emerged as the technology with novel applications.

Image acquisition — The large superficial arteries, in particular the carotid arteries (figure 1), can be visualized at high resolution with B-mode (or "brightness" mode) ultrasound using linear array transducers for superficial and vascular structures (typically broadband transducers with frequency ranges 5 to 15 MHz and a high signal to noise ratio are used). The spatial resolution obtained with these transducers is on the order of 0.05 mm axially and 0.2 mm laterally. In most scan protocols, carotid ultrasound images are obtained from the near and far walls of the right and left distal common carotid arteries, the carotid bifurcation (image 1), and the proximal internal carotid arterial segments. CIMT in an individual patient is therefore often a composite of intima-media thickness measurements of various arterial segments, sometimes under multiple angles of insonation to decrease measurement variability in follow-up scans.

Measurement technique — For CIMT measurements, longitudinal images of the carotid arteries are obtained in which the leading edges of the lumen-intima and media-adventitia interfaces (the "double-line pattern") of the arterial wall represent intima-media complex (image 1) [1,2]. Typically, normal common carotid CIMT at age 10 is approximately 0.4 to 0.5 mm, while from the fifth decade of life onward this progresses to 0.7 to 0.8 mm or more [3].

Since the arterial walls are submillimeter structures, performing CIMT measurements requires experience and craftsmanship, and standardized image acquisition is paramount. Sonographers should be well trained, and standardized ultrasound equipment and protocols should be used. Furthermore, image analysis should preferably be done offline, with dedicated software using standardized protocols and performed by expert technicians. Moreover, quality control results of scans and feedback to sonographers must have a rapid turnaround. Under these conditions, ultrasound CIMT measurement has excellent interscan as well as inter- and intraobserver reproducibility [4].

Use of ultrasound measurements in single- and multicenter studies — In trial design and logistics, bringing study subjects (recruitment), research personnel (training, certification) and equipment (availability, standardization) together, are major challenges. Ultrasound imaging is non-invasive, subject-friendly, and due to standardization of instrument settings and scan protocols and relatively low equipment and infrastructure costs, study size is easily scalable between single- and multicenter settings. This flexibility of application of ultrasound technologies is one of great logistic benefit in atherosclerosis studies [1,4].

Applications for CIMT measurements — The suggested indications for CIMT measurement have included:

Screening for atherosclerosis

Risk stratification for future cardiovascular disease-related events

Assessment of drug efficacy

The corresponding data for each of these indications along with recommendations regarding the use of CIMT measurement for each indication are discussed below.

CIMT for cardiovascular risk stratification — Cardiovascular risk prediction in asymptomatic individuals is based on risk scores. Although guidelines have based risk assessment on the use of multivariate risk models, their ability to predict future cardiovascular events has limitations [5-7]. In fact, a high percentage of cardiovascular events occur in persons at low and intermediate risk [8]. CIMT has been proposed as a potential tool to aid cardiovascular risk stratification as it comprises a direct measure of atherosclerosis, is associated with future cardiovascular events, and is a safe, inexpensive, and widely available technique [2,9,10]. (See "Atherosclerotic cardiovascular disease risk assessment for primary prevention in adults: Our approach".)

CIMT and future cardiovascular events — In patients without known cardiovascular disease (CVD), composite measures of CIMT of various segments, with or without the presence of atherosclerotic plaque, result in modest but statistically significant increases in net reclassification improvement when added to risk estimates based on traditional risk factors or risk models. Whether the improvement in risk stratification due to CIMT and plaque information translates into measurable health benefits for individuals or populations, or reductions in the cost of care, has not been established. Until additional data are available that directly correlate CIMT measurement with improvements in hard outcomes (ie, death, myocardial infarction, stroke), we do not recommend routine CIMT measurement.

Numerous prospective epidemiological studies have shown that CIMT is a predictor of future cardiovascular events, independent of traditional risk factors. In addition, three systematic reviews and meta-analyses have reviewed the one-time and serial use of CIMT for CVD risk prediction [11-13].

One-time CIMT measurement – In a systematic review and meta-analysis on the individual data of 14 studies of 45,828 asymptomatic individuals who underwent one-time CIMT measurement at baseline (median follow-up 10.8 years), the hazard ratio (per 0.10 mm adjusted mean common CIMT difference) for first myocardial infarction and stroke was 1.09 (95% CI, 1.07-1.12), for first myocardial infarction 1.08 (95% CI, 1.05-1.10), and for first stroke 1.12 (95% CI, 1.10-1.15) [11]. CIMT measures of other carotid artery segments and the presence of plaque showed similar relationships with future cardiovascular events [10,12,14-16].

While a one-time CIMT measurement can provide some predictive value for CVD risk assessment, we do not routinely perform CIMT measurement in most patients, preferring to use a standard cardiovascular risk assessment model based on traditional cardiac risk factors.

Serial CIMT measurements – In a systematic review and meta-analysis on the individual data of 16 studies of 36,984 patients without known CVD who underwent serial CIMT measurement (mean follow-up seven years), in which the yearly progression rates were calculated for various CIMT measures (mean and maximum CIMT values of the common, bifurcation, and internal carotid arteries), there was no association between progression of CIMT and future events [12]. These findings are corroborated by a more recent meta-analysis including 31 studies of 89,070 patients showing a consistent association between CIMT and the combined endpoint of myocardial infarction, stroke, and vascular death, while there was no association between CIMT change and vascular event risk [13]. While there are various potential methodological as well as biological explanations, there is no proof of a relation between CIMT progression and future cardiovascular events.

Because of this, we do not recommend the use of serial CIMT measurements for the purpose of CVD risk assessment.

Although CIMT independently predicts future cardiovascular events, some issues need to be addressed before CIMT can be considered for cardiovascular risk stratification. First, the addition of CIMT needs to show improvement in cardiovascular risk stratification when added to traditional risk scores, as expressed by improvement in the net reclassification index [10,17]. Second, an improvement by CIMT in cardiovascular risk stratification should translate into a measurable health benefit and should be cost effective [18].

Regarding the added value of mean common CIMT to the Framingham 10-year risk prediction of myocardial infarction and stroke, the previously mentioned meta-analysis showed a net reclassification improvement in all subjects of 0.8 percent, and in subjects at intermediate risk of 3.6 percent [11]. This minimal increase in net reclassification following the addition of mean common CIMT to the Framingham risk predictor was not felt to be useful for cardiovascular risk stratification.

Net reclassification improvement has also been investigated for CIMT measurement of other segments of the carotid arteries with mixed results.

In the ARIC study of 13,145 participants without known CVD, mean CIMT of all segments did show an improvement in reclassification of 7.1 percent in all subjects and 16.7 percent in subjects at intermediate risk [14]. Similar results were found in the IMPROVE study of 3703 asymptomatic subjects with at least three CVD risk factors, in which the net reclassification improvement in all subjects was 11.3 percent for mean CIMT and 10.5 percent for mean maximum CIMT of all segments [16].

By contrast, in the CAPS study in 4904 participants without known CVD, CIMT of each of the different segments (common, bifurcation, and internal carotid) did not result in an increase in the net reclassification improvement when added to traditional risk factors [19].

The effect of the presence of plaque (defined as maximum CIMT >1.5 mm) on risk classification has also been investigated. In the ARIC study mentioned above, the addition of presence of plaque to traditional risk factors increased the net reclassification improvement by 7.7 percent in all subjects and 17.7 percent in subjects at intermediate risk [14]. Similar results have been reported from the Framingham Offspring Study cohort [15].

Recommendations of others — The 2013 American College of Cardiology Foundation/American Heart Association guideline for the assessment of CVD risk does not recommend the routine use of CIMT in clinical practice for CVD risk assessment [20].

CIMT and CVD risk in specific populations — An appealing aspect of CIMT measurement is that it assesses the atherosclerotic disease process itself, which reflects the net effect of known and unknown hereditary and environmental factors. CIMT can therefore be used to assess cardiovascular risk in populations where risk estimation with traditional risk factors doesn't apply, such as populations with specific genetic mutations in lipid metabolism. Ideally, prospective observational studies are needed to determine CVD risk in such populations, and randomized controlled trials should be performed to establish if this risk can be ameliorated. However, considering the rareness of such mutations, these types of studies are unlikely to become available.

CIMT can aid in assessing whether such patients have accelerated atherosclerosis development. An example is provided by studies in asymptomatic patients with genetic mutations in HDL metabolism, such as patients with LCAT and ABCA1 deficiency [21,22]. CIMT studies have indicated accelerated atherosclerosis development in these populations, which can be informative and of important guidance for clinicians treating these patients. Children with familial hypercholesterolemia (FH) represent another population in which CIMT has proven to be a valuable tool. Guidelines advise starting treatment with cholesterol lowering medications in children with FH from age 10 years. These recommendations are for an important part based on data from CIMT studies [23,24]. These examples illustrate that CIMT can be an informative and clinically relevant tool to estimate CVD risk in specific populations.

CIMT for the assessment of drug efficacy — CIMT has frequently been utilized in clinical trials to test the efficacy of cardiovascular drugs and results are directly associated with other vascular beds, like the coronary arteries [25]. However, while CIMT is an efficient tool to monitor the effects of therapy in clinical trials, modification of therapy based on CIMT results has not been shown to alter hard end points (eg, death, myocardial infarction, stroke). As such, CIMT is not routinely used in clinical practice to monitor the effects of medical therapy and is not used as an instrument to assess therapeutic efficacy in the individual patient.

Lipid-lowering therapy — With regard to lipid-lowering medications, various placebo-controlled CIMT studies in the 1990s showed that atherosclerosis progression was retarded by statin use in patients with cardiovascular disease [25-28]. Subsequently, aggressive lipid lowering with statins also showed markedly reduced CIMT progression when compared with moderate lipid lowering with statins, which was consistent with subsequent observations in clinical end point studies [29,30]. Furthermore, several CIMT trials revealed a beneficial effect of statins on atherosclerosis progression in asymptomatic subjects [31-34] and proved safe and sensitive enough to pick up efficacious benefits of statin treatment, even at a very young age [24,35,36]. In addition to statins, the efficacy of numerous non-statin lipid-modifying medications on atherosclerosis progression, as measured by CIMT, has been evaluated (eg, niacin, pactimibe, torcetrapib, ezetimibe) [4,37-43].

Anti-hypertensive therapy — The effects of various antihypertensive drugs on atherosclerosis, as measured by CIMT, have also been reported in numerous trials. As examples:

Metoprolol decreased CIMT progression compared with placebo in subjects without cardiovascular disease (CVD) [44,45].

Amlodipine decreased CIMT progression compared with placebo in patients with coronary heart disease [46].

Conversely, ramipril did not show an effect on CIMT progression compared with placebo in patients with CVD or at high risk for CVD [47,48].

Other studies have compared the effect of different classes of blood pressure lowering drugs on CIMT progression [49-55].

Other medications — In addition to lipid-lowering medications and anti-hypertensive medications, antioxidants (eg, vitamin E, folic acid, vitamins B12 and B6), hormone replacement therapies (eg, estradiol, tibolone, raloxifene), glucose-lowering therapies (eg, rosiglitazone, pioglitazone, glimepiride), and anti-obesity medication (rimonabant) have also been investigated in CIMT studies [56-68].

CIMT as a surrogate marker to establish efficacy prior to large hard end point trials — CIMT measurement may be a useful surrogate marker of efficacy that can be used in small trials of new therapies prior to the initiation of a large-scale trial. In one study that investigated the agreement between the outcome of CIMT drug efficacy trials and morbidity and mortality studies investigating the same drug, the positive and negative predictive values of a CIMT trial to predict the outcome of a morbidity and mortality trial were 96 and 83 percent, respectively [69]. A meta-analysis of 119 randomized clinical trials involving 100.667 patients with an average follow-up of 3.7 years showed that interventions reducing CIMT progression were also likely to reduce CVD event rates. Each 10 micrometers per year reduction of CIMT progression, induced either by lipid-lowering, antidiabetic, antihypertensive, dietary, or other interventions, resulted in a relative risk for CVD of 0.91 (95% CI 0.87-0.94) [10].

This shows that in drug development, a CIMT trial can be used as a validated benchmark tool to guide the decision of whether or not to embark on a large-scale morbidity and mortality trial. The research, business, regulatory, and clinical impacts of these measurements are therefore of considerable importance in the decision making on acceptance and reimbursement of novel cardiovascular therapies.

CIMT MEASUREMENT BY MRI — CIMT can be measured using magnetic resonance imaging (MRI). However, given the additional complexity and cost of MRI when compared with ultrasound, CIMT measurement should not primarily be performed with MRI in most patients.

MRI does possess a number of important characteristics that make it well suited for the visualization of atherosclerosis. First, MRI is noninvasive, safe, and no ionizing radiation is involved. Second, MRI enables imaging of all stages of atherosclerosis (image 2), from healthy vessels to advanced disease in submillimeter resolution [70-73]. Furthermore, disparities in the spin-lattice relaxation time (T1), the spin-spin relaxation time (T2), and the proton density (PD) enable discrimination of plaque components such as intraplaque hemorrhage, lipid-rich necrotic core, and calcification (image 2) [70]. MRI of vessel wall thickness as well as imaging of plaque size and composition is highly reproducible [71,73].

The predictive value of carotid vessel wall thickness measurement by MRI for future cardiovascular events is currently unknown. However, MRI of vessel wall thickness is highly correlated with ultrasound carotid intima-media thickness (CIMT), so it is reasonable to expect that the predictive value of both modalities will be in the same order of magnitude [71]. Several smaller studies have been conducted to investigate the relation between plaque size and composition and future cardiovascular events [74-77]. Various observational studies have investigated the relationship between traditional cardiovascular risk factors and carotid vessel wall thickness and plaque size and composition measured with MRI [78,79]. Furthermore, atherosclerosis imaging with MRI has shown to be a valuable modality for the assessment of atherosclerosis progression in specific patient populations, as well as for the assessment of cardiovascular drug efficacy [21,22,80-82].

As such, CIMT has proven a strong research tool if well monitored and quality controlled [4,7,9,11-13].

SUMMARY AND RECOMMENDATIONS

Background – Ultrasound carotid intima-media thickness (CIMT) is a widely available, safe, and reproducible measure when performed by trained and certified sonographers with standardized equipment. (See 'Introduction' above and 'Image acquisition' above.)

Use in cardiovascular disease prediction – In patients without known cardiovascular disease (CVD), composite measures of CIMT of various segments, with or without the presence of atherosclerotic plaque, result in modest but statistically significant increases in net reclassification improvement when added to risk estimates based on traditional risk factors or risk models. Whether the improvement in risk stratification due to CIMT and plaque information translates into measurable health benefits for individuals or into reductions in the cost of care has not been established. We do not recommend routine CIMT measurement to assess cardiovascular disease risk in the individual patient. (See 'CIMT and future cardiovascular events' above.)

Use in research – CIMT is a well-validated research tool to investigate atherosclerosis development in epidemiological studies, provide insight in cardiovascular disease risk in specific populations, and to evaluate efficacy of preventive cardiovascular therapies in clinical trials. (See 'CIMT for the assessment of drug efficacy' above.)

No role in monitoring drug efficacy – CIMT is not recommended to be routinely used in clinical practice to monitor the effects of medical therapy in the individual patient. (See 'CIMT for the assessment of drug efficacy' above.)

MRI-based measurement – CIMT can be measured using magnetic resonance imaging (MRI). However, given the additional complexity and cost of MRI when compared with ultrasound, CIMT measurement should not primarily be performed with MRI in most patients. (See 'CIMT measurement by MRI' above.)

ACKNOWLEDGMENT — The UpToDate editorial staff thank Dr. John J. P. Kastelein for his past contributions as an author to prior versions of this topic review.

  1. de Groot E, van Leuven SI, Duivenvoorden R, et al. Measurement of carotid intima-media thickness to assess progression and regression of atherosclerosis. Nat Clin Pract Cardiovasc Med 2008; 5:280.
  2. Naqvi TZ, Lee MS. Carotid intima-media thickness and plaque in cardiovascular risk assessment. JACC Cardiovasc Imaging 2014; 7:1025.
  3. Iana Simova. Intima-media thickness: Appropriate evaluation and proper meausrement, described. E-Journal of the ESC Council for Cardiology Practice 2015; 13:1.
  4. Meuwese MC, de Groot E, Duivenvoorden R, et al. ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial. JAMA 2009; 301:1131.
  5. Pasternak RC, Abrams J, Greenland P, et al. 34th Bethesda Conference: Task force #1--Identification of coronary heart disease risk: is there a detection gap? J Am Coll Cardiol 2003; 41:1863.
  6. Akosah KO, Schaper A, Cogbill C, Schoenfeld P. Preventing myocardial infarction in the young adult in the first place: how do the National Cholesterol Education Panel III guidelines perform? J Am Coll Cardiol 2003; 41:1475.
  7. Øygarden H. Carotid Intima-Media Thickness and Prediction of Cardiovascular Disease. J Am Heart Assoc 2017; 6.
  8. Berry JD, Liu K, Folsom AR, et al. Prevalence and progression of subclinical atherosclerosis in younger adults with low short-term but high lifetime estimated risk for cardiovascular disease: the coronary artery risk development in young adults study and multi-ethnic study of atherosclerosis. Circulation 2009; 119:382.
  9. Redberg RF, Vogel RA, Criqui MH, et al. 34th Bethesda Conference: Task force #3--What is the spectrum of current and emerging techniques for the noninvasive measurement of atherosclerosis? J Am Coll Cardiol 2003; 41:1886.
  10. Willeit P, Tschiderer L, Allara E, et al. Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk: Meta-Analysis of 119 Clinical Trials Involving 100 667 Patients. Circulation 2020; 142:621.
  11. Den Ruijter HM, Peters SA, Anderson TJ, et al. Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. JAMA 2012; 308:796.
  12. Lorenz MW, Polak JF, Kavousi M, et al. Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data. Lancet 2012; 379:2053.
  13. Lorenz MW, Gao L, Ziegelbauer K, et al. Predictive value for cardiovascular events of common carotid intima media thickness and its rate of change in individuals at high cardiovascular risk - Results from the PROG-IMT collaboration. PLoS One 2018; 13:e0191172.
  14. Nambi V, Chambless L, Folsom AR, et al. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. J Am Coll Cardiol 2010; 55:1600.
  15. Polak JF, Pencina MJ, Pencina KM, et al. Carotid-wall intima-media thickness and cardiovascular events. N Engl J Med 2011; 365:213.
  16. Baldassarre D, Hamsten A, Veglia F, et al. Measurements of carotid intima-media thickness and of interadventitia common carotid diameter improve prediction of cardiovascular events: results of the IMPROVE (Carotid Intima Media Thickness [IMT] and IMT-Progression as Predictors of Vascular Events in a High Risk European Population) study. J Am Coll Cardiol 2012; 60:1489.
  17. Tzoulaki I, Liberopoulos G, Ioannidis JP. Assessment of claims of improved prediction beyond the Framingham risk score. JAMA 2009; 302:2345.
  18. Mark DB, Shaw LJ, Lauer MS, et al. 34th Bethesda Conference: Task force #5--Is atherosclerosis imaging cost effective? J Am Coll Cardiol 2003; 41:1906.
  19. Lorenz MW, Schaefer C, Steinmetz H, Sitzer M. Is carotid intima media thickness useful for individual prediction of cardiovascular risk? Ten-year results from the Carotid Atherosclerosis Progression Study (CAPS). Eur Heart J 2010; 31:2041.
  20. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63:2935.
  21. Duivenvoorden R, Holleboom AG, van den Bogaard B, et al. Carriers of lecithin cholesterol acyltransferase gene mutations have accelerated atherogenesis as assessed by carotid 3.0-T magnetic resonance imaging [corrected]. J Am Coll Cardiol 2011; 58:2481.
  22. Bochem AE, van Wijk DF, Holleboom AG, et al. ABCA1 mutation carriers with low high-density lipoprotein cholesterol are characterized by a larger atherosclerotic burden. Eur Heart J 2013; 34:286.
  23. Wiegman A, Gidding SS, Watts GF, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J 2015; 36:2425.
  24. Luirink IK, Wiegman A, Kusters DM, et al. 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia. N Engl J Med 2019; 381:1547.
  25. de Groot E, Jukema JW, Montauban van Swijndregt AD, et al. B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS). J Am Coll Cardiol 1998; 31:1561.
  26. Crouse JR 3rd, Byington RP, Bond MG, et al. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol 1995; 75:455.
  27. Hodis HN, Mack WJ, LaBree L, et al. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomized controlled clinical trial. Ann Intern Med 1996; 124:548.
  28. MacMahon S, Sharpe N, Gamble G, et al. Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group. Circulation 1998; 97:1784.
  29. Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001; 357:577.
  30. Taylor AJ, Kent SM, Flaherty PJ, et al. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002; 106:2055.
  31. Furberg CD, Adams HP Jr, Applegate WB, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 1994; 90:1679.
  32. Mercuri M, Bond MG, Sirtori CR, et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. Am J Med 1996; 101:627.
  33. Salonen R, Nyyssönen K, Porkkala E, et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995; 92:1758.
  34. Crouse JR 3rd, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007; 297:1344.
  35. Braamskamp MJAM, Langslet G, McCrindle BW, et al. Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label). Circulation 2017; 136:359.
  36. Wiegman A, de Groot E, Hutten BA, et al. Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. Lancet 2004; 363:369.
  37. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004; 110:3512.
  38. Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin 2006; 22:2243.
  39. Blankenhorn DH, Selzer RH, Crawford DW, et al. Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two- and four-year reduction of intima-media thickness measured by ultrasound. Circulation 1993; 88:20.
  40. Mack WJ, Selzer RH, Hodis HN, et al. One-year reduction and longitudinal analysis of carotid intima-media thickness associated with colestipol/niacin therapy. Stroke 1993; 24:1779.
  41. Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007; 356:1620.
  42. Bots ML, Visseren FL, Evans GW, et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007; 370:153.
  43. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358:1431.
  44. Hedblad B, Wikstrand J, Janzon L, et al. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001; 103:1721.
  45. Wiklund O, Hulthe J, Wikstrand J, et al. Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. Stroke 2002; 33:572.
  46. Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000; 102:1503.
  47. Lonn E, Yusuf S, Dzavik V, et al. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001; 103:919.
  48. MacMahon S, Sharpe N, Gamble G, et al. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. J Am Coll Cardiol 2000; 36:438.
  49. Zanchetti A, Crepaldi G, Bond MG, et al. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS--a randomized double-blind trial. Stroke 2004; 35:2807.
  50. Zanchetti A, Bond MG, Hennig M, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002; 106:2422.
  51. Simon A, Gariépy J, Moyse D, Levenson J. Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. Circulation 2001; 103:2949.
  52. Borhani NO, Mercuri M, Borhani PA, et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA 1996; 276:785.
  53. Stanton AV, Chapman JN, Mayet J, et al. Effects of blood pressure lowering with amlodipine or lisinopril on vascular structure of the common carotid artery. Clin Sci (Lond) 2001; 101:455.
  54. Hoogerbrugge N, de Groot E, de Heide LH, et al. Doxazosin and hydrochlorothiazide equally affect arterial wall thickness in hypertensive males with hypercholesterolaemia (the DAPHNE study). Doxazosin Atherosclerosis Progression Study in Hypertensives in the Netherlands. Neth J Med 2002; 60:354.
  55. Ludwig M, Stapff M, Ribeiro A, et al. Comparison of the effects of losartan and atenolol on common carotid artery intima-media thickness in patients with hypertension: results of a 2-year, double-blind, randomized, controlled study. Clin Ther 2002; 24:1175.
  56. Hodis HN, Mack WJ, LaBree L, et al. Alpha-tocopherol supplementation in healthy individuals reduces low-density lipoprotein oxidation but not atherosclerosis: the Vitamin E Atherosclerosis Prevention Study (VEAPS). Circulation 2002; 106:1453.
  57. Magliano D, McNeil J, Branley P, et al. The Melbourne Atherosclerosis Vitamin E Trial (MAVET): a study of high dose vitamin E in smokers. Eur J Cardiovasc Prev Rehabil 2006; 13:341.
  58. Durga J, Bots ML, Schouten EG, et al. Effect of 3 y of folic acid supplementation on the progression of carotid intima-media thickness and carotid arterial stiffness in older adults. Am J Clin Nutr 2011; 93:941.
  59. Hodis HN, Mack WJ, Dustin L, et al. High-dose B vitamin supplementation and progression of subclinical atherosclerosis: a randomized controlled trial. Stroke 2009; 40:730.
  60. Zoungas S, McGrath BP, Branley P, et al. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial. J Am Coll Cardiol 2006; 47:1108.
  61. Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 135:939.
  62. Bots ML, Evans GW, Riley W, et al. The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study. Eur Heart J 2006; 27:746.
  63. Colacurci N, Fornaro F, Cobellis L, et al. Raloxifene slows down the progression of intima-media thickness in postmenopausal women. Menopause 2007; 14:879.
  64. Byington RP, Furberg CD, Herrington DM, et al. Effect of estrogen plus progestin on progression of carotid atherosclerosis in postmenopausal women with heart disease: HERS B-mode substudy. Arterioscler Thromb Vasc Biol 2002; 22:1692.
  65. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006; 296:2572.
  66. Langenfeld MR, Forst T, Hohberg C, et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 2005; 111:2525.
  67. Hedblad B, Zambanini A, Nilsson P, et al. Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study. J Intern Med 2007; 261:293.
  68. O'Leary DH, Reuwer AQ, Nissen SE, et al. Effect of rimonabant on carotid intima-media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial. Heart 2011; 97:1143.
  69. Peters SA, den Ruijter HM, Grobbee DE, Bots ML. Results from a carotid intima-media thickness trial as a decision tool for launching a large-scale morbidity and mortality trial. Circ Cardiovasc Imaging 2013; 6:20.
  70. Yuan C, Beach KW, Smith LH Jr, Hatsukami TS. Measurement of atherosclerotic carotid plaque size in vivo using high resolution magnetic resonance imaging. Circulation 1998; 98:2666.
  71. Duivenvoorden R, de Groot E, Elsen BM, et al. In vivo quantification of carotid artery wall dimensions: 3.0-Tesla MRI versus B-mode ultrasound imaging. Circ Cardiovasc Imaging 2009; 2:235.
  72. Duivenvoorden R, de Groot E, Afzali H, et al. Comparison of in vivo carotid 3.0-T magnetic resonance to B-mode ultrasound imaging and histology in a porcine model. JACC Cardiovasc Imaging 2009; 2:744.
  73. Li F, Yarnykh VL, Hatsukami TS, et al. Scan-rescan reproducibility of carotid atherosclerotic plaque morphology and tissue composition measurements using multicontrast MRI at 3T. J Magn Reson Imaging 2010; 31:168.
  74. Underhill HR, Yuan C, Yarnykh VL, et al. Predictors of surface disruption with MR imaging in asymptomatic carotid artery stenosis. AJNR Am J Neuroradiol 2010; 31:487.
  75. Takaya N, Yuan C, Chu B, et al. Association between carotid plaque characteristics and subsequent ischemic cerebrovascular events: a prospective assessment with MRI--initial results. Stroke 2006; 37:818.
  76. Altaf N, Daniels L, Morgan PS, et al. Detection of intraplaque hemorrhage by magnetic resonance imaging in symptomatic patients with mild to moderate carotid stenosis predicts recurrent neurological events. J Vasc Surg 2008; 47:337.
  77. Parmar JP, Rogers WJ, Mugler JP 3rd, et al. Magnetic resonance imaging of carotid atherosclerotic plaque in clinically suspected acute transient ischemic attack and acute ischemic stroke. Circulation 2010; 122:2031.
  78. Wagenknecht L, Wasserman B, Chambless L, et al. Correlates of carotid plaque presence and composition as measured by MRI: the Atherosclerosis Risk in Communities Study. Circ Cardiovasc Imaging 2009; 2:314.
  79. Wasserman BA, Sharrett AR, Lai S, et al. Risk factor associations with the presence of a lipid core in carotid plaque of asymptomatic individuals using high-resolution MRI: the multi-ethnic study of atherosclerosis (MESA). Stroke 2008; 39:329.
  80. Fayad ZA, Mani V, Woodward M, et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 2011; 378:1547.
  81. Lee JM, Robson MD, Yu LM, et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol 2009; 54:1787.
  82. Underhill HR, Yuan C, Zhao XQ, et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am Heart J 2008; 155:584.e1.
Topic 91564 Version 20.0

References

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟